589 related articles for article (PubMed ID: 31462429)
1. SRSF3-Regulated RNA Alternative Splicing Promotes Glioblastoma Tumorigenicity by Affecting Multiple Cellular Processes.
Song X; Wan X; Huang T; Zeng C; Sastry N; Wu B; James CD; Horbinski C; Nakano I; Zhang W; Hu B; Cheng SY
Cancer Res; 2019 Oct; 79(20):5288-5301. PubMed ID: 31462429
[TBL] [Abstract][Full Text] [Related]
2. CircSMARCA5 Inhibits Migration of Glioblastoma Multiforme Cells by Regulating a Molecular Axis Involving Splicing Factors SRSF1/SRSF3/PTB.
Barbagallo D; Caponnetto A; Cirnigliaro M; Brex D; Barbagallo C; D'Angeli F; Morrone A; Caltabiano R; Barbagallo GM; Ragusa M; Di Pietro C; Hansen TB; Purrello M
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29415469
[TBL] [Abstract][Full Text] [Related]
3. Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3.
Fuentes-Fayos AC; Vázquez-Borrego MC; Jiménez-Vacas JM; Bejarano L; Pedraza-Arévalo S; L-López F; Blanco-Acevedo C; Sánchez-Sánchez R; Reyes O; Ventura S; Solivera J; Breunig JJ; Blasco MA; Gahete MD; Castaño JP; Luque RM
Brain; 2020 Dec; 143(11):3273-3293. PubMed ID: 33141183
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic splicing factor SRSF3 regulates ILF3 alternative splicing to promote cancer cell proliferation and transformation.
Jia R; Ajiro M; Yu L; McCoy P; Zheng ZM
RNA; 2019 May; 25(5):630-644. PubMed ID: 30796096
[TBL] [Abstract][Full Text] [Related]
5. Splicing factor SRSF1 promotes gliomagenesis via oncogenic splice-switching of MYO1B.
Zhou X; Wang R; Li X; Yu L; Hua D; Sun C; Shi C; Luo W; Rao C; Jiang Z; Feng Y; Wang Q; Yu S
J Clin Invest; 2019 Feb; 129(2):676-693. PubMed ID: 30481162
[TBL] [Abstract][Full Text] [Related]
6. Functional genomics analyses of RNA-binding proteins reveal the splicing regulator SNRPB as an oncogenic candidate in glioblastoma.
Correa BR; de Araujo PR; Qiao M; Burns SC; Chen C; Schlegel R; Agarwal S; Galante PA; Penalva LO
Genome Biol; 2016 Jun; 17(1):125. PubMed ID: 27287018
[TBL] [Abstract][Full Text] [Related]
7. SRSF5 functions as a novel oncogenic splicing factor and is upregulated by oncogene SRSF3 in oral squamous cell carcinoma.
Yang S; Jia R; Bian Z
Biochim Biophys Acta Mol Cell Res; 2018 Sep; 1865(9):1161-1172. PubMed ID: 29857020
[TBL] [Abstract][Full Text] [Related]
8. PPM1G promotes the progression of hepatocellular carcinoma via phosphorylation regulation of alternative splicing protein SRSF3.
Chen D; Zhao Z; Chen L; Li Q; Zou J; Liu S
Cell Death Dis; 2021 Jul; 12(8):722. PubMed ID: 34290239
[TBL] [Abstract][Full Text] [Related]
9. SON drives oncogenic RNA splicing in glioblastoma by regulating PTBP1/PTBP2 switching and RBFOX2 activity.
Kim JH; Jeong K; Li J; Murphy JM; Vukadin L; Stone JK; Richard A; Tran J; Gillespie GY; Flemington EK; Sobol RW; Lim SS; Ahn EE
Nat Commun; 2021 Sep; 12(1):5551. PubMed ID: 34548489
[TBL] [Abstract][Full Text] [Related]
10. Loss of TDP43 inhibits progression of triple-negative breast cancer in coordination with SRSF3.
Ke H; Zhao L; Zhang H; Feng X; Xu H; Hao J; Wang S; Yang Q; Zou L; Su X; Wang L; Wu C; Wang Y; Nie J; Jiao B
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3426-E3435. PubMed ID: 29581274
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of splicing factor SRSF3 induces p53β, an alternatively spliced isoform of p53 that promotes cellular senescence.
Tang Y; Horikawa I; Ajiro M; Robles AI; Fujita K; Mondal AM; Stauffer JK; Zheng ZM; Harris CC
Oncogene; 2013 May; 32(22):2792-8. PubMed ID: 22777358
[TBL] [Abstract][Full Text] [Related]
12. Serine/arginine-rich splicing factor 3 (SRSF3) regulates homologous recombination-mediated DNA repair.
He X; Zhang P
Mol Cancer; 2015 Aug; 14():158. PubMed ID: 26282282
[TBL] [Abstract][Full Text] [Related]
13. Inclusion of hnRNP L Alternative Exon 7 Is Associated with Good Prognosis and Inhibited by Oncogene SRSF3 in Head and Neck Squamous Cell Carcinoma.
Xu L; Shen J; Jia J; Jia R
Biomed Res Int; 2019; 2019():9612425. PubMed ID: 31828152
[TBL] [Abstract][Full Text] [Related]
14. CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer.
Chen S; Yang C; Wang ZW; Hu JF; Pan JJ; Liao CY; Zhang JQ; Chen JZ; Huang Y; Huang L; Zhan Q; Tian YF; Shen BY; Wang YD
J Hematol Oncol; 2021 Apr; 14(1):60. PubMed ID: 33849617
[TBL] [Abstract][Full Text] [Related]
15. Exon 9 skipping of apoptotic caspase-2 pre-mRNA is promoted by SRSF3 through interaction with exon 8.
Jang HN; Lee M; Loh TJ; Choi SW; Oh HK; Moon H; Cho S; Hong SE; Kim DH; Sheng Z; Green MR; Park D; Zheng X; Shen H
Biochim Biophys Acta; 2014 Jan; 1839(1):25-32. PubMed ID: 24321384
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic SRSF3 in health and diseases.
Jia R; Zheng ZM
Int J Biol Sci; 2023; 19(10):3057-3076. PubMed ID: 37416784
[TBL] [Abstract][Full Text] [Related]
17. A genome landscape of SRSF3-regulated splicing events and gene expression in human osteosarcoma U2OS cells.
Ajiro M; Jia R; Yang Y; Zhu J; Zheng ZM
Nucleic Acids Res; 2016 Feb; 44(4):1854-70. PubMed ID: 26704980
[TBL] [Abstract][Full Text] [Related]
18. Serine/Arginine-Rich Splicing Factor 3 Modulates the Alternative Splicing of Cytoplasmic Polyadenylation Element Binding Protein 2.
DeLigio JT; Stevens SC; Nazario-Muñoz GS; MacKnight HP; Doe KK; Chalfant CE; Park MA
Mol Cancer Res; 2019 Sep; 17(9):1920-1930. PubMed ID: 31138601
[TBL] [Abstract][Full Text] [Related]
19. Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression.
Ferrarese R; Harsh GR; Yadav AK; Bug E; Maticzka D; Reichardt W; Dombrowski SM; Miller TE; Masilamani AP; Dai F; Kim H; Hadler M; Scholtens DM; Yu IL; Beck J; Srinivasasainagendra V; Costa F; Baxan N; Pfeifer D; von Elverfeldt D; Backofen R; Weyerbrock A; Duarte CW; He X; Prinz M; Chandler JP; Vogel H; Chakravarti A; Rich JN; Carro MS; Bredel M
J Clin Invest; 2014 Jul; 124(7):2861-76. PubMed ID: 24865424
[TBL] [Abstract][Full Text] [Related]
20. The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma.
Aldave G; Gonzalez-Huarriz M; Rubio A; Romero JP; Ravi D; Miñana B; Cuadrado-Tejedor M; García-Osta A; Verhaak R; Xipell E; Martinez-Vélez N; de la Rocha AA; Puigdelloses M; García-Moure M; Marigil M; Gállego Pérez-Larraya J; Marín-Bejar O; Huarte M; Carro MS; Ferrarese R; Belda-Iniesta C; Ayuso A; Prat-Acín R; Pastor F; Díez-Valle R; Tejada S; Alonso MM
Neuro Oncol; 2018 Jun; 20(7):930-941. PubMed ID: 29373718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
